AU2001277534B9 - Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity - Google Patents
Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity Download PDFInfo
- Publication number
- AU2001277534B9 AU2001277534B9 AU2001277534A AU2001277534A AU2001277534B9 AU 2001277534 B9 AU2001277534 B9 AU 2001277534B9 AU 2001277534 A AU2001277534 A AU 2001277534A AU 2001277534 A AU2001277534 A AU 2001277534A AU 2001277534 B9 AU2001277534 B9 AU 2001277534B9
- Authority
- AU
- Australia
- Prior art keywords
- compounds
- treatment
- prophylaxis
- obesity
- mammals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims description 76
- 238000000034 method Methods 0.000 title claims description 56
- 208000008589 Obesity Diseases 0.000 title claims description 41
- 235000020824 obesity Nutrition 0.000 title claims description 41
- 238000011282 treatment Methods 0.000 title claims description 40
- 238000011321 prophylaxis Methods 0.000 title claims description 34
- 230000000694 effects Effects 0.000 claims description 34
- 241000124008 Mammalia Species 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 27
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 210000001789 adipocyte Anatomy 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 230000001773 anti-convulsant effect Effects 0.000 claims description 7
- 230000004132 lipogenesis Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000010998 test method Methods 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000010352 biotechnological method Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 description 19
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- -1 compound topiramate Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
DECLARATION
I, ALISON WINIFRED PENFOLD, Dip. (Translation), of Lloyd Wise, Commonwealth House, 1-19 New Oxford Street, London WC1A 1LW, do hereby certify that I am conversant with the English and German languages and am a competent translator thereof and that to the best of my knowledge and belief the following is a true and correct translation into the English language of the documents in respect of International Publication No. WO 02/07821 Al in the name of Solvay Pharmaceuticals GmbH filed in the Federal Republic of Germany.
Signed this 23rd day of January 2003 CtQhO^ ^sQZtU Method of discovering compounds suitable for the treatment and/or prophylaxis of obesity The present invention relates to a method of discovering compounds suitable for the treatment and/or prophylaxis of obesity. The invention further relates to the use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the central nervous system CNS), for the preparation of drugs for the treatment and/or prophylaxis of obesity.
Today, especially in the developed industrial nations, obesity is an increasingly serious problem for the health of the population, being caused predominantly by unbalanced and excessively high-fat nutrition. The increase in the percentage of overweight people in the population is being accompanied by an increase in the consequences of obesity, which range from personal discontentment to cardiovascular diseases or even certain forms of diabetes. There are therefore already a number of therapeutic procedures aimed at the treatment or prophylaxis of obesity. One example which may be mentioned is lipase-inhibitory compounds, which reduce lipolysis in the intestinal tract and thereby cut down the energy yield from the food intake. Thus, in this therapeutic procedure, at least part of the alimentary fats is excreted undecomposed. It is however desirable to have other novel therapeutic procedures for the treatment and/or prophylaxis of obesity which can complement the previously known forms cl of therapy.
a ,It has now been found, surprisingly, that compounds which are capable of inhibiting de novo lipogenesis in mammals, especially man, are advantageously suitable for the effective treatment and/or prophylaxis of obesity. Particularly good results are achieved by administering the above-mentioned compounds Cc over prolonged periods, for example for periods of several weeks.
The invention therefore relates to a method of discovering compounds c suitable for the treatment and/or prophylaxis of obesity, characterised in that those compounds are selected which are capable of inhibiting de novo c lipogenesis in mammals, in particular humans, by inhibiting the activity of at least one carboanhydrase of sub-types II and/or V occurring in mammals, wherein at least one said compound is brought into contact with at least one said carboanhydrase, and those compounds which inhibit the activity of at least one said carboanhydrase are then identified.
De novo lipogenesis (abbreviated hereafter to DNL) is understood as meaning the synthesis of endogenous fatty acids from carbohydrates in the mammalian organism. This synthetic reaction takes place in the cytosol of body cells and is based on the so-called citric acid cycle or Krebs-Martius cycle. In this cycle, in an endogenous biochemical reaction, citrate is ultimately synthesized from the two components pyruvate, which originates from carbohydrates, and bicarbonate via different intermediates including maleate, fumarate and a-ketoglutarate. If citrate is synthesized in excess, it can be converted via the intermediate acetyl-coenzyme A to free fatty acids lipidic subsequent products), which form fats and can then be stored in fat cells adipocytes). The excessive storage of fats formed from fatty acids in body cells can quite generally lead to obesity. A variety of enzymes participate in the citric acid cycle. The turnover of the citrate cycle depends substantially on the amount of bicarbonate available. The amount of bicarbonate available in turn depends on the rate at which it can be formed from carbon dioxide. This bicarbonate-yielding equilibrium reaction is catalyzed by so-called carboanhydrases. Of the known carboanhydrases and isozymes thereof, predominantly carboanhydrase isozymes of subtypes II CA II) and V CA V) participate, in mammals, in the catalysis of reactions which provide bicarbonate for the citric acid cycle. Carboanhydrases of subtype V, being present in the mitochondria, have a particular role to play. The citric acid cycle also takes place in the mitochondria.
There are various conceivable possibilities for inhibiting DNL in mammalian cells, all of which aim to reduce the turnover of the citric acid cycle. This makes it possible to cut down the concentration of citrate produced in excess, which is available for the synthesis of fatty acids. According to the present invention, DNL can preferably be inhibited by inhibiting the carboanhydrases which catalyze the reactions yielding bicarbonate for the citric acid cycle. For the purpose of the invention, it is 0 possible to inhibit preferably CA V.
c Compounds which are capable of inhibiting carboanhydrases non- Sspecifically non-specific or conventional CA inhibitors) are known per se and have been used for a relatively long time in various therapeutic fields, mainly as 00oo diuretics or in ophthalmology. A survey of fields of use of such conventional CA inhibitors can be found e.g. in C.T. Supuran, Expert Opinion on Therapeutic rq Patents, 10 (2000) 575 600/ "Specific CA inhibitors", on the other hand, is to be understood to mean compounds which largely inhibit only one CA subtype c CA V) or a defined group of CA subtypes. The use of conventional CA inhibitors for the specific treatment and/or prophylaxis of obesity is not known.
SIt is generally accepted that the overwhelming majority of known cases of obesity are attributable to the comparatively excessive proportion of exogenous fats in the food intake. In highly developed countries like the USA, up to 30% of the food consumed by obese people is in the form of fats. According to 'current knowledge, fatty acid deposits leading to obesity accordingly originate predominantly from an excessive intake of alimentary fats. These cannot be influenced by the inhibition of DNL, which targets carbohydrate metabolism.
Thus, although a reduction in the storage of fatty acids in adipocytes is also achieved by DNL inhibition, the latter has hitherto been regarded as an unsuitable starting point for the treatment and/or prophylaxis of obesity in man because of its inherently small contribution to the storage of fatty acids in body cells. A summary of the opinions expressed by experts in this subject can be found for example in M.K. Hellerstein, European Journal of Clinical Nutrition 53 (1999) 53 -65. This view prevailing among experts has so far stood in the way of the specific search for drugs for the treatment and/or prophylaxis of obesity which are based on the principle of DNL inhibition, or of their development.
Within the framework of the present invention, it has now been found, surprisingly, that compounds which are capable of inhibiting DNL in mammals, especially man, can be used effectively for the treatment and/or prophylaxis of obesity, particularly if these compounds are administered to the patients in question over prolonged periods of e.g.
more than six weeks. Accordingly, over prolonged periods, significant reductions in the body weight of obese persons can be achieved by DNL inhibition even though DNL per se makes only a relatively small contribution to the body fat stored in adipocytes. Thus, by means of DNL inhibition over prolonged periods, this inherently small effect can accumulate in such a way that it makes a significant overall contribution to the reduction in body weight.
Using the compound topiramate as an example, it can be shown that the method according to the invention is indeed suitable for specifically discovering compounds suitable for the treatment and/or prophylaxis of obesity.
Topiramate is an antiepileptic known from EP 0 138 441 A2.
Topiramate is also known to have a multifactorial pharmacological spectrum of action. Thus topiramate can block the tension-dependent sodium channels and hence stabilize the membrane potential of cells, it activates the GABA receptors and thereby enhances GABA-mediated inhibition, it acts as a carboanhydrase inhibitor and, lastly, it is capable of inhibiting the AMPA/kainate receptors, a subtype of the glutamate receptors, thereby inhibiting the appearance of AMPA-induced flows.
Accordingly, topiramate exhibits pronounced effects on the CNS. It is not known whether the antiepileptic properties of topiramate are attributable to the pharmacologically relevant factors mentioned above.
It is known from WO 98/00130 that topiramate also possesses pharmacological properties which make it appear suitable for the treatment of obesity. These properties were discovered by chance as side effects in long-term studies on epileptic patients. It is not yet known which pharmacological properties of topiramate are responsible for the weight loss observed in epileptic patients.
Topiramate is one of a group of anticonvulsant compounds of a general formula I indicated in WO 98/00130 as suitable for the treatment of obesity.
By the method according to the invention, it was now possible to show that topiramate is a potent CA inhibitor, especially a potent inhibitor of carboanhydrases of subtypes II and V occurring in mammals, and that topiramate is capable of effectively inhibiting DNL in mammalian cells. Thus the method according to the invention made it possible for the first time to prove that the hitherto inexplicable pharmacological side effects of topiramate leading to weight loss in epileptic patients are based substantially on its ability effectively to inhibit DNL in mammals. It is accordingly to be expected that the method according to the invention will make it possible in the future to discover compounds suitable for the treatment and/or prophylaxis of obesity. The method according to the invention thus opens up for the first time the possibility of discovering, with comparative speed and ease, pharmacologically potent compounds which act according to the principle of DNL inhibition. By virtue of the present invention, compounds acting according to the abovementioned principle and suitable for the treatment and/or prophylaxis of obesity can now be selected, at least in a first preliminary selection process, without lengthy and expensive in vivo tests such as test-animal feeding experiments.
These results are surprising as earlier investigations into the pharmacological properties of topiramate indicated that its CA-inhibitory activity was always unexceptional or even rather low and of no therapeutic importance (cf. e.g.
B.E. Maryanoff et al., Journal of Medicinal Chemistry (1987) 880 887; B.E. Maryanoff et al., Journal of Medicinal Chemistry 41 (1998) 1315 1343; S.J. Dodgson et al., Epilepsia 41 (2000) p. 35 p. 39). In the earlier investigations mentioned above, the CA-inhibitory activity of topiramate was always determined using test solutions containing CA from different mammals, which still contained various body constituents such as blood or organ tissue.
In a first embodiment of the method according to the invention, compounds suitable for the treatment and/or O prophylaxis of obesity can be discovered by selecting as suitable those cN compounds which are capable of inhibiting the activity of at least one a carboanhydrase occurring in mammals wherein at least one test compound can be brought into contact with at least one carboanhydrase and those compounds 00oo O 5 which inhibit the activity of at least one carboanhydrase of subtypes II and/or V can then be identified in a manner known per se. In this embodiment it is n preferable to use carboanhydrases which occur in mammals such as man or rodents, for example rats, mice or guinea-pigs. It is particularly preferable to use ci carboanhydrases which occur in man. For example, suitable carboanhydrases O 10 can be isolated from the above-mentioned mammals and purified if desired, or c they can preferably be prepared by chemical or biotechnological methods known per se.
In a preferred variant of this first embodiment, the change in activity of the carboanhydrases under the influence of the test compounds can be determined in an in vitro enzyme activity test known per se, the carboanhydrases being present as isolated enzymes which have been at least substantially freed of impurities. It is preferable to use carboanhydrases which have been prepared by chemical or biotechnological methods as these can be used in especially pure form. In vitro activity tests for determining the activity of carboanhydrases are known per se.
The in vitro enzyme activity tests which are suitable within the scope of the present invention to determine changes in the activity of carboanhydrases are for example the measurement of the change in pH value under the influence of carboanhydrases, (cf. K. M. Wilbur, N. G.
Andersen, Journal of Biological Chemistry 176 (1948) 147 154; G. Sanyal, T. H. Maren, Journal of Biological Chemistry 256 (1981) 608 612), the stop-flow measurement method (cf. R. G. Khalifah, Journal of Biological Chemistry 246 (1971) 2561 2573) or the 4-nitrophenylacetateesterase method (cf. Y. Pocker, J. T. Stone, Journal of the American Chemical Society 87 (1965) 5497 5498). In the latter test, the rate of hydrolysis of 4-nitrophenylacetate under the influence of the carboanhydrases to be investigated is determined, in which the property of carboanhydrases also to act as esterases is utilised.
According to the invention, a test method for determination of the CA-inhibitory properties of compounds which is described by C.T. Supuran et al., European Journal of Medicinal Chemistry 33 (1998) 577 594 (cf. p. 592 in particular; cited hereafter as "Supuran et or by A. Scozzafava et al., Journal of Medicinal Chemistry 42 (1999) 3690 3700 (cf. p. 3697 in particular; cited hereafter as "Scozzafava et is preferentially suitable in this context. Within the framework of the disclosure of the present invention, express reference is hereby made to said test methods described by Supuran et al. and Scozzafava et al. Compounds which have IC 50 values of at least 10 umol/l or below higher activity) in one of the above-mentioned in vitro standard activity tests according to Supuran et al. or Scozzafava et al. can be selected as suitable CA-inhibitory compounds CA inhibitors) in terms of the present invention. If the activity of human CA subtypes is to be determined, methods other than the 4-nitrophenylacetate-esterase method may be better suited. In particular, methods which make it possible also to have relatively rapid reactions may be suitable.
In an enzyme activity test (originally described by Y.
Pocker and J. T. Stone, Biochemistry 6 (1967) 668-678) operating according to the 4-nitrophenylacetate-esterase method described by Scozzafava et al. (vide supra) in terms of the present invention it was demonstrated that topiramate has a pronounced inhibitory action on human carboanhydrase of subtype II (IC 50 5 nmol/l) obtained by biotechnological methods, and that this inhibitory action is considerably stronger than the inhibitory action caused by the conventional CA inhibitors acetazolamide or methazolamide measured as reference substances. The human carboanhydrase of subtype II was obtained by the method described by Scozzafava et al.
In the same test, it was demonstrated that topiramate also has a pronounced inhibitory action on carboanhydrase of the subtype Va of mice mCA Va) which is obtained by biotechnological processes (IC 50 74 nmol/l). In a departure from the test procedure described by Scozzafava et al, in this case the enzyme mCA Va was used in a concentration of 120 nM. The mCA Va was obtained in known manner by the method described by H.R. Heck et al., Journal of Biological Chemistry 269 (1994) 24742 24746. To this end, the strain of bacteria Escherichia coli BL 21 (DE3) was used, which was used with a plasmid vector which contained the sequence coding for mCA Va under the control of the T7 promoter which can be induced by isopropyl-P-Dthiogalactopyranoside (IPTG). The bacterial culture was inoculated at 37 0 C with stirring into a Luria-Bertani liquid medium containing ampicillin (100 pg/ml) and its growth was monitored by spectrophotometry at 600 nm. Once the bacterial culture had entered the exponential growth phase, IPTG was added in a final concentration of 1 mmol/l.
After 3 hours' incubation time (37 0 C with stirring), the bacterial culture was centrifuged at 7000 x g for 15 min and the supernatant was discarded. The resulting pellet was taken up in 0.1 vol twice-distilled water, and lysozyme (100 pg/ml) was added thereto. The cell lysis took place under ultrasound treatment. To this end, aliquotes of 10 ml of the resulting bacterial suspension were poured into a glass vessel which was open at the top, and each of these samples was treated with ultrasound 4 times for 3 min.
After each ultrasound pulse, the absorption of the samples was determined at 600 nm, for which each 100 pl of a sample was diluted with 900 ul twice-distilled water. The end point was reached once the value of the 600 nm absorption of a sample was about 1/10 of the initial value. Once cell lysis had taken place, CaC12-binding buffer (from Stratagene) was added, and the resulting cell lysate was poured on to a calmodulin Affinity resin column for purification. The purification is based on the high affinity of the calmodulin domain which is bound to the resin to the calmodulin binding peptide tag which is present at the N-terminal end of the expressed mCA Va protein. The purification was effected in known manner (cf.
manual "Affinity LIC Cloning and Protein Purification Kit Manual" from Stratagene).
In a second embodiment of the method according to the invention, compounds suitable for the treatment and/or prophylaxis of obesity can be discovered by selecting those compounds which are capable of reducing the amount of metabolic products formed in the citric acid cycle of isolated living mammalian cells or of lipidic subsequent products of the citric acid cycle. Suitable metabolic products of the citric acid cycle whose amount is measurably reduced under the influence of the test compounds are acid-soluble metabolic products such as citrate, maleate, fumarate and/or a-ketoglutarate. Citrate is preferred. Furthermore, lipidic subsequent products of the citric acid cycle, such as free fatty acids, are suitable as metabolic products. Lastly, in this second embodiment, the ability of the test compounds to inhibit the activity of at least one carboanhydrase occurring in mammals is also determined, although the test model used is set up differently from the first embodiment mentioned.
The process of the second embodiment is based on the principle of determining in known manner the uptake of radioactivity from substrates of the citric acid cycle labelled with the 14 C-isotope into metabolic intermediate products or subsequent products of the citric acid cycle of isolated, living mammalian cells and comparing the results obtained with the results which were obtained under otherwise identical conditions, but under the influence of CA-inhibitory compounds. Isolated living cells of rodents such as rats, mice or guinea-pigs, or of man, are preferably used in this variant of the method. Human cells are preferred. If cells of rodents are used, these can be adipocytes or hepatocytes. Adipocytes of rodents are preferred. If human cells are used, adipocytes or hepatocytes may be used. Human hepatocytes are preferred.
The mammalian cells used in this variant of the method can be obtained by conventional culture and/or cloning processes. Natural or biotechnologically modified mammalian cells may be used. If the uptake of radioactivity in acid-soluble intermediate products of the citrate cycle is to be determined, preferably 14C-hydrogen carbonate NaH[14C]0 3 is used as the 14 C-labelled substrate. If the uptake of radioactivity in lipidic subsequent products of the citrate cycle is to be determined, preferably
[U-
14 C]glucose is used as the 14 C-labelled substrate.
A preferred variant of this second embodiment for determining the ability of compounds to inhibit DNL in mammals is indicated by S.A. Hazen et al. in FASEB Journal (1996) 481 490 (cited hereafter as "Hazen et Within the framework of the disclosure of the present invention, express reference is hereby made to said test method described by Hazen et al. Compounds which, in said test according to Hazen et al., significantly inhibit the incorporation of radioactivity from 14C-labelled substances which can serve as precursors in the citric acid cycle, for example the incorporation of 14 C-bicarbonate into citrate, maleate, fumarate and/or a-ketoglutarate, with an IC 50 value of at least 10 pmol/l or below higher activity) can be selected as suitable compounds in terms of the present invention.
In a test model corresponding to that described by Hazen et al., which was carried out within the framework of the present invention, topiramate exhibited a pronounced inhibitory effect on the formation of acid-soluble metabolic products of the citric acid cycle of rat adipocytes of the 3T3-F442A cell line obtained by biotechnological methods. This inhibitory effect of topiramate (IC 50 348 nmol/l) was markedly more pronounced than the effect of the conventional CA inhibitor ethoxzolamide measured as a reference substance.
In a particularly preferred variant of the method according to the invention for discovering compounds suitable for the treatment and/or prophylaxis of obesity, those compounds are selected which, in the above-mentioned first embodiment of the method, especially in an abovementioned in vitro enzyme activity test, have been selected as suitable for inhibiting at least one carboanhydrase occurring in mammals, and which additionally, in the abovementioned second embodiment of the method, have been selected as suitable for reducing the amount of metabolic products formed in the citric acid cycle of isolated living mammalian cells as well. In the first embodiment of the method, the ability of compounds to inhibit carboanhydrases occurring in mammals can be checked rapidly and effectively. The second embodiment of the method provides, inter alia, clues as to whether the compounds investigated are also capable of penetrating mitochondria of living mammalian cells where CA V is located. Suitable compounds can be selected by carrying out the first and second abovementioned embodiments in parallel or consecutively in either order.
c According to the invention, compounds which are capable of inhibiting DNL ain mammals are suitable for the preparation of drugs for the treatment and/or 00prophylaxis of obesity. Compounds selected here are those which are capable of inhibiting carboanhydrases of subtypes II and/or V occurring in mammals. The selected compounds must of course be physiologically compatible and meet the Sdemands generally made on pharmaceutical active substances, e.g. regarding safety and compatibility. Particularly preferred compounds are those which are capable specifically of inhibiting CA II and/or CA V, especially CA V.
Previously known compounds with a CA-inhibitory effect which cause a Sreduction in patients' body weight after prolonged administration, for example topiramate, also have pronounced effects directed towards the CNS, for instance anticonvulsant effects. Side effects directed towards the CNS are often undesirable for compounds which are intended for long-term administration aimed at the treatment and/or prophylaxis of obesity. Compounds which have been selected by the above-mentioned method according to the invention as suitable for the treatment and/or prophylaxis of obesity can therefore additionally be tested for effects directed towards the CNS. For example, the compounds can be tested for any anticonvulsant properties which may be present. An example of a suitable method of testing compounds for anticonvulsant properties is the so-called "supramaximal electroshock test" SES test, occasionally also referred to as the "maximal electroshock test" or MES test) according to G. Chen et al., Proceedings of the Society for Experimental Biology and Medicine 87 (1954) 334 339 (cited hereafter as "Chen et and J.E.P. Toman et al., Journal of Neurophysiology 9 (1946) 231 (cited hereafter as "Toman et Within the framework of the disclosure of the present invention, express reference is hereby made to said test method described by Chen et al. and Toman et al.
Thus compounds which are aimed at the treatment and/or prophylaxis of obesity by administration to patients over prolonged periods should be substantially ineffective in the above-mentioned SES test according to Chen et al. and Toman et al., and should preferably have no effects to be regarded as significant according to the criteria conventionally applied to this test, even in higher doses of at least 100 mg/kg p.o. protective dose, PD 50 according to G. Chen et al. 2100 mg/kg the PD 50 values given by G. Chen et al. substantially correspond here to the more common indication of dose as the minimum effective dose, MED). Compounds which have been selected as suitable in the above-mentioned method of discovering compounds, and which additionally are substantially ineffective in the above-mentioned MES test according to Chen et al., are particularly suitable for the preparation of drugs for the treatment and/or prophylaxis of obesity.
Said SES (or MES) tests are standard pharmacological tests and can be performed as routine methods by appropriate service providers "Panlabs").
I
0 The compounds discovered by the method according to the invention as c being suitable for the treatment and/or prophylaxis of obesity can usually be Scontained as drugs with conventional pharmaceutical auxiliary substances in galenic formulations, e.g. tablets, capsules, suppositories or solutions. The galenic formulations can be prepared by methods known per se using conventional solid or liquid excipients, e.g. lactose, starch or talcum or liquid Sparaffins, and/or using conventional pharmaceutical auxiliary substances, for example tablet disintegrants, solubilizers or preservatives. Pharmaceutical c preparations suitable according to the invention are for example also known from IP 0 138 441 A2 and from WO 98/00130.
In a preferred embodiment of the invention one or more compounds identified by the method of the invention are administered to a mammal as a method of treatment or prophylaxis of obesity.
Claims (4)
- 46298.July.05 J Claims 0 S1. A method of discovering compounds suitable for 00 the treatment and/or prophylaxis of obesity, characterised in that those compounds are selected which are capable of inhibiting de novo lipogenesis in mammals, M in particular humans, by inhibiting the activity of at least one carboanhydrase of sub-types II and/or V C occurring in mammals, wherein at least one said compound is brought into contact with at least one said C carboanhydrase, and those compounds which inhibit the activity of at least one said carboanhydrase are then identified.
- 2. A method as claimed in claim 1 wherein carboanhydrases occurring in rodents or man are used.
- 3. A method as claimed in claim 2 wherein carboanhydrases occurring in man are used.
- 4. A method as claimed in claim 1 wherein carboanhydrases of subtype V occurring in mammals, especially man, are used. 4. A method as claimed in claim 1 wherein the carboanhydrases are present as isolated enzymes obtained by chemical or biotechnological methods, and wherein the change in activity of the carboanhydrases under the influence of the compounds is determined in an in vitro enzyme activity test. 6. A method as claimed in claim 1 wherein the compounds selected as suitable are those which are capable of reducing the amount of metabolic products formed in the citric acid cycle of isolated living mammalian cells. 46298.July.05 7. A method as claimed in claim 6 wherein the reduction in the amount of citrate, maleate, fumarate and/or a-ketoglutarate formed in the citric acid cycle of the cells and/or the reduction of the formation of lipidic subsequent products of the citric acid cycle under the influence of the compounds is determined. 8. A method as claimed in claim 6 wherein isolated living cells of rodents or man are used. 9. A method as claimed in claim 8 wherein adipocytes or hepatocytes are used. A method of discovering compounds suitable for the treatment and/or prophylaxis of obesity, characterized in that compounds are selected which have been identified as suitable compounds in a method as claimed in claim 5 and additionally in a method as claimed in claim 6. 11. A method of discovering compounds suitable for the treatment and/or prophylaxis of obesity, wherein compounds are selected which have been identified as suitable compounds in a method as claimed in claim 1, and which have additionally been identified as substantially ineffective in a standard test for the determination of anticonvulsant properties. 12. A use of compounds which are capable of inhibiting de novo lipogenesis in mammals by inhibiting at least one carboanhydrase occurring in mammals according to a method as defined in claim 1 for the preparation of a drug for the treatment and/or prophylaxis of obesity. 13. A use as claimed in claim 12 of compounds which are substantially free of anticonvulsant properties. c 14. A use of compounds which have been identified for the first time by a amethod as claimed in claim 1 as suitable for the treatment and/or prophylaxis of obesity for the preparation of a drug for the treatment and/or prophylaxis of 00 Sobesity. 15. A method of treatment or prophylaxis of obesity wherein one or more compounds which are capable of inhibiting de novo lipogenesis in mammals by c inhibiting at least one carboanhydrase occurring in mammals, as defined in claim 1, are administered to a mammal in need of said treatment. 16. A method of treatment as defined in claim 15 wherein said compounds are substantially free of anticonvulsant properties. 17. A method of treatment or prophylaxis of obesity wherein one or more compounds which have been identified for the first time by the method of claim 1 are administered to a mammal in need of said treatment. 18. A method of discovering compounds suitable for the treatment and prophylaxis of obesity substantially as hereinbefore described with reference to the described test methods. 19. The use of a compound identified by the method of claim 18 for the treatment or prophylaxis of obesity. DATED this 7th day of September 2005 SOLVAY PHARMACEUTICALS GMBH WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P22438AU00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10035227.8 | 2000-07-20 | ||
DE10035227A DE10035227A1 (en) | 2000-07-20 | 2000-07-20 | Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
PCT/EP2001/008051 WO2002007821A1 (en) | 2000-07-20 | 2001-07-12 | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2001277534A1 AU2001277534A1 (en) | 2002-05-02 |
AU2001277534B2 AU2001277534B2 (en) | 2005-09-29 |
AU2001277534B9 true AU2001277534B9 (en) | 2006-02-23 |
Family
ID=7649538
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001277534A Ceased AU2001277534B9 (en) | 2000-07-20 | 2001-07-12 | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
AU7753401A Pending AU7753401A (en) | 2000-07-20 | 2001-07-12 | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU7753401A Pending AU7753401A (en) | 2000-07-20 | 2001-07-12 | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1307262B1 (en) |
JP (1) | JP2004504053A (en) |
KR (1) | KR100818827B1 (en) |
CN (1) | CN1443085B (en) |
AR (1) | AR028730A1 (en) |
AT (1) | ATE278441T1 (en) |
AU (2) | AU2001277534B9 (en) |
BR (1) | BR0112547A (en) |
CA (1) | CA2416647A1 (en) |
CZ (1) | CZ2003156A3 (en) |
DE (2) | DE10035227A1 (en) |
DZ (1) | DZ3393A1 (en) |
ES (1) | ES2230346T3 (en) |
HK (1) | HK1057499A1 (en) |
HU (1) | HUP0302309A3 (en) |
IL (2) | IL153971A0 (en) |
MX (1) | MXPA02012907A (en) |
NO (1) | NO20030233L (en) |
NZ (1) | NZ523960A (en) |
PL (1) | PL201165B1 (en) |
PT (1) | PT1307262E (en) |
RU (1) | RU2268721C2 (en) |
SK (1) | SK287607B6 (en) |
TR (1) | TR200402670T4 (en) |
TW (1) | TWI274157B (en) |
UA (1) | UA74588C2 (en) |
WO (1) | WO2002007821A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2395503C2 (en) | 2004-05-19 | 2010-07-27 | Зольвай Фармасьютиклз Гмбх | Medicinal agents containing n-sulfamoyl-n'-arylpiperazines meant for preventing or treating obesity and related conditions |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
AU2006249577A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
TW200804393A (en) | 2005-11-14 | 2008-01-16 | Solvay Pharm Gmbh | Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
AR058389A1 (en) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
TW200812573A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
AU2008209320B2 (en) | 2007-01-25 | 2013-05-30 | NAIA Metabolic, Inc. | Insulin sensitisers and methods of treatment |
BRPI0915890A2 (en) | 2008-06-23 | 2015-11-03 | Janssen Pharmaceutica Nv | (2s) - (-) - n- (6-chloro-2,3-dihydro-benzo [1,4] dioxin-2-ylmethyl) sulfamide crystalline form |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
RU2653478C2 (en) * | 2012-05-24 | 2018-05-08 | Найя Матаболик Инк. | Method of improvement of liver function |
CN106770611B (en) * | 2016-12-22 | 2019-01-29 | 广西师范大学 | A method of entering mitochondria for cell in-situ detection small molecule compound |
RU2771430C1 (en) * | 2021-09-21 | 2022-05-04 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Method for the quantitative determination of anticonvulsants in the blood plasma of patients with epilepsy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552897A (en) * | 1983-02-01 | 1985-11-12 | American Cyanamid Company | Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom |
US5597797A (en) * | 1990-06-07 | 1997-01-28 | Genentech, Inc. | Method for treatment or prevention of obesity |
US5869452A (en) * | 1994-11-10 | 1999-02-09 | Monash University | Treatment of obesity |
US6288095B1 (en) * | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD1486G2 (en) * | 1992-10-29 | 2001-11-30 | Genentech, Inc. | Method for treatment or prevention of obesity |
ATE224189T1 (en) * | 1996-06-28 | 2002-10-15 | Ortho Mcneil Pharm Inc | ANTICONVULSIVE SULFAMATE DERIVATIVES FOR THE TREATMENT OF OBESITY |
-
2000
- 2000-07-20 DE DE10035227A patent/DE10035227A1/en not_active Withdrawn
-
2001
- 2001-06-15 AR ARP010102883A patent/AR028730A1/en unknown
- 2001-07-12 AU AU2001277534A patent/AU2001277534B9/en not_active Ceased
- 2001-07-12 CA CA002416647A patent/CA2416647A1/en not_active Abandoned
- 2001-07-12 AU AU7753401A patent/AU7753401A/en active Pending
- 2001-07-12 PT PT01955345T patent/PT1307262E/en unknown
- 2001-07-12 AT AT01955345T patent/ATE278441T1/en active
- 2001-07-12 BR BR0112547-8A patent/BR0112547A/en not_active Application Discontinuation
- 2001-07-12 PL PL363518A patent/PL201165B1/en not_active IP Right Cessation
- 2001-07-12 MX MXPA02012907A patent/MXPA02012907A/en active IP Right Grant
- 2001-07-12 KR KR1020037000620A patent/KR100818827B1/en not_active IP Right Cessation
- 2001-07-12 EP EP01955345A patent/EP1307262B1/en not_active Expired - Lifetime
- 2001-07-12 NZ NZ52396001A patent/NZ523960A/en not_active IP Right Cessation
- 2001-07-12 HU HU0302309A patent/HUP0302309A3/en unknown
- 2001-07-12 WO PCT/EP2001/008051 patent/WO2002007821A1/en active IP Right Grant
- 2001-07-12 CN CN018129730A patent/CN1443085B/en not_active Expired - Fee Related
- 2001-07-12 TR TR2004/02670T patent/TR200402670T4/en unknown
- 2001-07-12 DE DE50104023T patent/DE50104023D1/en not_active Expired - Lifetime
- 2001-07-12 RU RU2003104803/14A patent/RU2268721C2/en not_active IP Right Cessation
- 2001-07-12 ES ES01955345T patent/ES2230346T3/en not_active Expired - Lifetime
- 2001-07-12 DZ DZ013393A patent/DZ3393A1/en active
- 2001-07-12 CZ CZ2003156A patent/CZ2003156A3/en unknown
- 2001-07-12 IL IL15397101A patent/IL153971A0/en unknown
- 2001-07-12 JP JP2002513551A patent/JP2004504053A/en active Pending
- 2001-07-12 SK SK61-2003A patent/SK287607B6/en not_active IP Right Cessation
- 2001-07-16 TW TW090117382A patent/TWI274157B/en not_active IP Right Cessation
- 2001-12-07 UA UA2003021453A patent/UA74588C2/en unknown
-
2003
- 2003-01-15 IL IL153971A patent/IL153971A/en not_active IP Right Cessation
- 2003-01-17 NO NO20030233A patent/NO20030233L/en unknown
-
2004
- 2004-01-15 HK HK04100307.4A patent/HK1057499A1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552897A (en) * | 1983-02-01 | 1985-11-12 | American Cyanamid Company | Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom |
US6288095B1 (en) * | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
US5597797A (en) * | 1990-06-07 | 1997-01-28 | Genentech, Inc. | Method for treatment or prevention of obesity |
US5869452A (en) * | 1994-11-10 | 1999-02-09 | Monash University | Treatment of obesity |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
Non-Patent Citations (1)
Title |
---|
Supuran Ct et al * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7238470B2 (en) | Method of treating or inhibiting obesity | |
AU2001277534B9 (en) | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity | |
Honkanan et al. | Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases | |
Carter et al. | Decreased urinary output of tyramine and its metabolites in depression | |
Ienaga et al. | Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers | |
US20050169903A1 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof | |
KR101472083B1 (en) | Pharmaceutical Compositions for Preventing or Treating Cancers Comprising ENOblock as an Active Ingredient | |
Gomez-Paloma et al. | Chemistry and biology of anti-inflammatory marine natural products. Phospholipase A2 inhibitors | |
US20070173545A1 (en) | Activation of hypoxia-inducible gene expression | |
ZA200300444B (en) | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity. | |
Widholm | Evidence for compartmentation of tryptophan in cultured plant tissues: free tryptophan levels and inhibition of anthranilate synthetase | |
KR20070092767A (en) | Method of detecting effect of controlling synoviolin activity | |
US20120088839A1 (en) | Composition for regulating cellular senescence comprising [n-2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide | |
Lee et al. | Rat malonyl-CoA decarboxylase; cloning, expression in E. coli and its biochemical characterization | |
US20040161794A1 (en) | Biosynthesis of HIF | |
KR20230110972A (en) | Anticancer composition comprising MARCH6 inhibitor | |
CN118021831A (en) | Application of Protodioscin as ACE2 Agonist | |
CN118105369A (en) | Eight compounds capable of improving ACE2 activity | |
Nautiyal | A Protein in Search of Function: NIPSNAP1 in Mitochondrial Branched-chain Amino Acid Metabolon, Brain and Apoptosis | |
EP1534322A1 (en) | Minibrain homologous proteins involved in the regulation of energy homeostasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
SREP | Specification republished | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |